for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PDS Biotechnology Corp

PDSB.OQ

Latest Trade

1.67USD

Change

-0.05(-2.91%)

Volume

80,292

Today's Range

1.65

 - 

1.78

52 Week Range

0.62

 - 

6.66

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.72
Open
1.78
Volume
80,292
3M AVG Volume
32.60
Today's High
1.78
Today's Low
1.65
52 Week High
6.66
52 Week Low
0.62
Shares Out (MIL)
15.36
Market Cap (MIL)
25.65
Forward P/E
-1.43
Dividend (Yield %)
--

Latest Developments

More

Pds Biotechnology - On June 23, Board Appointed Michael King As Interim CFO

Pds Biotechnology Reports Q1 Loss Per Share Of $0.39

PDS Biotechnology Announces Resignation Of Andrew Saik As CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PDS Biotechnology Corp

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Industry

Biotechnology & Drugs

Contact Info

25B VREELAND ROAD

FLORHAM PARK, NJ

07932

United States

+1.908.7901212

https://www.pdsbiotech.com

Executive Leadership

Stephen C. Glover

Independent Chairman of the Board

Frank Bedu-Addo

President, Chief Executive Officer, Director

Michael King

Interim Chief Financial Officer

Gregory L. Conn

Chief Scientific Officer

Lauren Wood

Chief Medical Officer

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-33.400

2019

-1.440

2020(E)

-1.170
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-78.43
Return on Equity (TTM)
-64.75

Latest News

Latest News

BRIEF-PDS Biotechnology And Farmacore Biotechnology To Co-Develop PDS0204 Covid-19 Vaccine

* PDS BIOTECHNOLOGY AND FARMACORE BIOTECHNOLOGY ANNOUNCE CO-DEVELOPMENT OF PDS0204 COVID-19 VACCINE

BRIEF-Pds Biotech Announces Initiation Of Phase 2 Trial Of Pds0101 Led By The National Cancer Institute

* PDS BIOTECH ANNOUNCES INITIATION OF PHASE 2 TRIAL OF PDS0101 LED BY THE NATIONAL CANCER INSTITUTE

BRIEF-PDS Biotechnology Announces Publication At American Society Of Clinical Oncology (ASCO) 2020

* PDS BIOTECHNOLOGY ANNOUNCES PUBLICATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2020 Source text for Eikon: Further company coverage:

BRIEF-Pds Biotechnology Reports Q1 Loss Per Share Of $0.39

* PDS BIOTECHNOLOGY REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2020 AND PROVIDES BUSINESS UPDATE

BRIEF-PDS Biotechnology Initiates Novel Vaccine Development Programs For Covid-19

* PDS BIOTECHNOLOGY INITIATES NOVEL VACCINE DEVELOPMENT PROGRAMS FOR COVID-19 AND UNIVERSAL INFLUENZA; DELAY OF PDS0101 VERSATILE-002 TRIAL

BRIEF-PDS Biotechnology Announces Resignation Of Andrew Saik As CFO

* PDS BIOTECHNOLOGY ANNOUNCES RESIGNATION OF ANDREW SAIK AS CFO

BRIEF-Pds Biotechnology Announces Commencement Of Work Under A Pre-Clinical Tie-up With Farmacore Biotechnology For Tuberculosis

* PDS BIOTECHNOLOGY ANNOUNCES COMMENCEMENT OF WORK UNDER A PRE-CLINICAL COLLABORATION WITH FARMACORE BIOTECHNOLOGY FOR TUBERCULOSIS

BRIEF-PDS Biotechnology Corp Announces Pricing Of Public Offering Of About $12 mln Shares

* PDS BIOTECHNOLOGY CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF APPROXIMATELY $12 MILLION OF SHARES OF COMMON STOCK

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up